Blue Jet Healthcare Ltd
NSE: BLUEJET BSE: 544009Pharma
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
₹416
52W: ₹325 — ₹1028
PE 24.6 · Book ₹72.4 · +475% vs bookMarket Cap₹7,215 Cr
Stock P/E24.6Price to Earnings
ROCE39.8%Return on Capital
ROE30.2%Return on Equity
Div. Yield0.28%Face Value ₹2
Strengths
- +Company is almost debt free.
- +Company is expected to give good quarter
- +Company has a good return on equity (ROE) track record: 3 Years ROE 26.8%
Shareholding Pattern
Promoters79.81%
FIIs0.89%
DIIs4.51%
Public14.8%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 86% | 86% | 86% | 86% | 86% | 79.81%▼6.2 | 79.81% | 79.81% |
| FIIs | 2.02% | 2.18%▲0.2 | 1.1%▼1.1 | 2.28%▲1.2 | 1.97%▼0.3 | 1.83%▼0.1 | 1.14%▼0.7 | 0.89%▼0.2 |
| DIIs | 2.14% | 1.75%▼0.4 | 2.02%▲0.3 | 1.33%▼0.7 | 0.95%▼0.4 | 3.63%▲2.7 | 4.65%▲1.0 | 4.51%▼0.1 |
| Public | 9.83% | 10.06%▲0.2 | 10.87%▲0.8 | 10.38%▼0.5 | 11.08%▲0.7 | 14.74%▲3.7 | 14.41%▼0.3 | 14.8%▲0.4 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 |
| Expenses | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 |
| Operating Profit | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 |
| OPM % | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% | 24% |
| Net Profit | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 | 40 |
| EPS ₹ | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 |
AI Insights
Revenue Trend
TTM revenue at ₹1,053Cr, up 2.2% YoY. OPM at 34%.
Debt Position
Borrowings at ₹21Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.
Capex Cycle
CWIP at ₹159Cr (52% of fixed assets). Significant capex underway — growth runway building.
Institutional Flow
DIIs: 4.51% (+0.81pp change). FIIs: 0.89% (-2.04pp change). Promoters hold 79.81%.
Margin & Efficiency
ROCE improving from 0% (Mar 2020) to 40% (Mar 2025). Working capital days: 157.
Valuation
PE 24.6x with 39.8% ROCE. Price is 475% above book value of ₹72.4. Dividend yield: 0.28%.
Recent Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
- Closure of Trading Window 24 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2025-26 results.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Mar - Investor one-to-one meeting with Muddy Waters Capital on March 16, 2026; no unpublished price-sensitive information disclosed.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 28 Feb - Groundbreaking for Vizag facility; Board-approved Phase 1 ₹1,000 crore; potential up to ₹2,300 crore.
- Company Update 19 Feb - Blue Jet to hold Bhoomi Pujan for new Rambilli manufacturing facility on Feb 28, 2026.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Rating update 16 Dec 2025 from care